Robin Vos
Katholieke Universiteit Leuven
AirwayInternal medicineSurgeryPathologyCardiologyIntensive care medicineImmunologyFEV1/FVC ratioBronchiolitis obliteransLungNeutrophiliaBronchoalveolar lavageBronchiolitisAzithromycinLung transplantationPrimary Graft DysfunctionTransplantationMedicineCohortPulmonary function testingGastroenterology
343Publications
42H-index
4,386Citations
Publications 346
Newest
#1Ruth Van Daele (Katholieke Universiteit Leuven)H-Index: 4
#2Joost Wauters (Katholieke Universiteit Leuven)H-Index: 25
Last. Isabel Spriet (Katholieke Universiteit Leuven)H-Index: 29
view all 7 authors...
BACKGROUND Isavuconazole is a triazole antifungal drug, approved for the treatment of invasive aspergillosis and mucormycosis. It has been previously reported that an interaction between flucloxacillin and voriconazole may lead to subtherapeutic voriconazole exposure, when used concomitantly. Since isavuconazole is also metabolised via cytochrome P450 enzymes, the same interaction may be expected. OBJECTIVES We aim to document exposure to isavuconazole in patients concomitantly treated with fluc...
Source
#1Arno Vanstapel (Katholieke Universiteit Leuven)H-Index: 7
#2Birgit Weynand (Universitaire Ziekenhuizen Leuven)
Last. Stijn E. Verleden (Katholieke Universiteit Leuven)H-Index: 38
view all 10 authors...
Source
#1Tinne Goos (Katholieke Universiteit Leuven)H-Index: 2
#2Laurens J. De Sadeleer (Katholieke Universiteit Leuven)H-Index: 9
Last. Robin Vos (Katholieke Universiteit Leuven)H-Index: 42
view all 13 authors...
Abstract null null Randomized placebo-controlled trials demonstrated the efficacy of antifibrotic treatment in non-IPF progressive fibrosing ILD (fILD). Currently, there is no consensus on how progression should be defined and clinical data of non-IPF fILD patients in a real-world setting are scarce. null Non-IPF fILD patients presenting at the University Hospitals Leuven between 2012 and 2016 were included. Different definitions of progression according to the selection criteria of the INBUILD,...
Source
#1A. Frick (Medical University of Vienna)H-Index: 3
#2C. Tji Gan (UG: University of Groningen)
Last. Peter Jaksch (Medical University of Vienna)H-Index: 32
view all 12 authors...
#1Milou van Bruchem (Katholieke Universiteit Leuven)
Last. Serge VogelaarH-Index: 2
view all 7 authors...
Source
#1Jef Verbeek (Katholieke Universiteit Leuven)H-Index: 12
#2Casper Vrij (Katholieke Universiteit Leuven)
Last. Diethard MonbaliuH-Index: 35
view all 13 authors...
Background null There is paucity of data on the prevalence, adequate timing and outcome of solid organ transplantation after SARS-CoV-2 infection and the kinetics of IgG antibodies in these patients. null Methods null SARS-CoV-2 anti-nucleocapsid (N) IgG and PCR via nasopharyngeal swab were analyzed in all patients within 24h before liver and/or kidney transplantation. Kinetics of IgG antibodies were analysed and compared with an immune-competent cohort. null Results null Between May 1st 2020 an...
Source
#1Lise Boey (Katholieke Universiteit Leuven)H-Index: 4
#2Ans Curinckx (Katholieke Universiteit Leuven)H-Index: 1
Last. Corinne Vandermeulen (Katholieke Universiteit Leuven)H-Index: 24
view all 10 authors...
Background The burden of human papillomavirus (HPV) in HIV-infected persons and solid organ transplant (SOT) recipients is high. Clinical trials on HPV vaccines in HIV-infected persons and particularly in SOT recipients have been sparse to date, included low numbers of participants and none of them assessed the nine-valent HPV (9vHPV). We investigated the immunogenicity with respect to HPV types 6/11/16/18/31/33/45/52/58 and the safety of the 9vHPV vaccine in HIV-infected persons and recipients ...
Source
#1Maria Crespo (HUP: Hospital of the University of Pennsylvania)H-Index: 12
#2Tamara Claridge (UPenn: University of Pennsylvania)
Last. A. Cochrane (Inova Fairfax Hospital)H-Index: 6
view all 26 authors...
Patients with connective tissues disease (CTD) are often on immunomodulatory agents before lung transplantation (LTx). Till now, there's no consensus on the safety of using these agents perioperative and post-transplant. The International Society for Heart and Lung Transplantation-supported consensus document on LTx in patients with CTD addresses the risk and contraindications of perioperative and post-transplant management of the biologic disease-modifying antirheumatic drugs (bDMARD), kinase i...
Source
#1Dirk Van Raemdonck (Katholieke Universiteit Leuven)H-Index: 63
#2Laurens J. Ceulemans (Katholieke Universiteit Leuven)H-Index: 14
Last. Geert Verleden (Katholieke Universiteit Leuven)H-Index: 70
view all 4 authors...
Source
#1Stephanie Detailleur (Katholieke Universiteit Leuven)H-Index: 1
#2Robin Vos (Katholieke Universiteit Leuven)H-Index: 42
Last. Pieter GoeminneH-Index: 26
view all 3 authors...
In this review paper, we discuss the characteristics that define severe bronchiectasis and which may lead to deterioration of noncystic fibrosis bronchiectasis. These characteristics were used to establish the current severity scores: bronchiectasis severity index (BSI), FACED, and E-FACED (exacerbation frequency, forced expiratory volume in 1 second, age, colonization, extension and dyspnea score). They can be used to predict mortality, exacerbation rate, hospital admission, and quality of life...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.